Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
Exparel
bupivacaine liposome
Brand names: Exparel
| Form | Strength |
|---|---|
| SUSPENSION, INJECTABLE | 1.3% (13.3 mg/mL) |
Last updated: Jun. 14, 2022
- High Alert: CAUTION: See High-Alert Medication Policy
- Restricted Formulary Restricted Medication
In April 2022, the P&T Committee voted to remove liposomal bupivacaine (Exparel) from formulary, with a target implementation of August 1, 2022.
See the SBAR for more details.